JSR North America Holdings, Inc. is a privately held corporation operating in the US. Our activities span the North American region, serving global clients in the semiconductor, drug discovery, biopharmaceutical, clinical research and clean energy solutions markets.

Garratt-Callahan Company is one of the leading providers of expert industrial water treatment solutions. Offering comprehensive water treatment solutions and expert consulting services backed by 117+ years of experience, we optimize system performance to extend equipment life, reduce health and safety risks, and minimize operating costs. We are guided by our responsibility to provide our customers with unparalleled customer service and effective, dependable water treatment solutions. Garratt-Callahan takes a proactive scientific approach to prevent problems before they occur so that our customers can spend more time running their business and less time trying to fix it. Specialties We utilize the most current, proven technology and treat our customers’ facilities with the same care and conscientiousness that we would with our own. We offer a full range of chemical and equipment solutions, created in our certified laboratory that follows State and Federal EPA standards. We also ensure that our water treatment products are certified in compliance with the international standards of quality of ISO 9001:2015 by NSF-ISR. Our water treatment services include: * Boiler Water Treatment * Cooling Water Treatment * Wastewater Solutions * LAP Certified In-house Laboratory * Water Management Plans * Legionella Mitigation * Secondary Disinfection * Water Treatment Training ASSE/IAPMO/ANSI 12080 Water Safety Training With the global COVID-19 pandemic and virus variants, water safety is even more critical. Our team is trained and certified with the implementation of ASHRAE 188-2018 to minimize the risk of Legionellosis. In 2020, ASHRAE adopted the American Society of Sanitary Engineers (ASSE) 10280. A growing number of our field technicians are certified under the new ASSE 12080 program.

Coherus is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immunotherapies to treat cancer and the commercialization of our portfolio of FDA-approved therapeutics. We are building a leading oncology company backed by in-house expertise and an established infrastructure from our diversified portfolio of FDA-approved biosimilar products. If you are interested in joining a highly innovative and exciting company, please visit our careers webpage at http://www.coherus.com/careers/ for a list of career opportunities.

IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company pioneering the development of engineered IgM antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. IgM antibodies have inherent properties that we believe may enable them to bind more strongly to targets on the surface of cells than comparable IgG antibodies. We believe our proprietary IgM antibody technology platform is particularly well suited for developing T cell engagers, receptor cross-linking agonists, targeted cytokines, and target neutralizers. Our lead product candidate, Imvotamab, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, and it is currently in two Phase 2 clinical trials for the treatment of relapsed and/or refractory diffuse large B cell lymphoma and follicular lymphoma. Our second product candidate is IGM-8444, an IgM antibody targeting Death Receptor 5 (DR5) for the treatment of patients with relapsed and/or refractory solid and hematologic malignancies, and it is currently in a Phase 1 clinical trial. Also in our product pipeline is IGM-7354 and IGM-2644. IGM-7354 is an anti-PD-L1 IgM antibody that targets the delivery of interleukin-15 (IL-15) cytokines to the area of PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma.

Gritstone bio brings together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to develop the next-generation of vaccines for cancer and infectious disease. With our unique approach to immuno-oncology and infectious diseases, we seek to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy diseased cells by targeting select antigens. We started with a focus on tumor-specific neoantigens and more recently extended our programs to include viral antigens displayed on the surface of virus-infected cells. The biology underlying immune system recognition of targets on the surface of abnormal cells is common to both anti-tumor and anti-viral immunity. Consequently, we believe that activating and directing the immune system to these targets could offer an important opportunity to extend the benefits of immunotherapy for more patients.